FindTrial
Sign In

Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06955104
Enrollment
145
Registered
2025-05-02
Start date
2025-04-03
Completion date
2025-07-30
Last updated
2025-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Brief summary

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia

Detailed description

To evaluate the efficacy and safety of JW0108+C2407 in dyslipidemia patients

Interventions

DRUGJW0108 + C2407

JW0108 + C2407

DRUGJW0108 + C2407 placebo

JW0108 + C2407 placebo

Sponsors

JW Pharmaceutical
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age of 19 years old at the time of written informed consent * Patients with dyslipidemia

Exclusion criteria

* Secondary dyslipidemia * Patient who does not meet the specified TG, LDL-C level

Design outcomes

Primary

MeasureTime frameDescription
Percent change from baseline in LDL-CWeek 8Check LDL-C

Secondary

MeasureTime frameDescription
Efficacy and Safety: Change from baseline in LDL-C (mg/dL)Week 8Check LDL-C

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026